CRVS

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune diseases and cancer. Its lead program, soquelitinib, is an oral therapy that selectively inhibits ITK to modulate immune system signaling pathways. The company is advancing a pipeline of investigational medicines and collaborates with partners to further its clinical-stage programs, aiming to improve treatment options for patients with serious diseases.